Physician profile
John M Strother
NPI 1518922111
$2,671.17
in general payments reported to CMS, 2019-2025
47 companies · $668 in 2025
The $668 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $104 · 2021: $98.02 · 2022: $349 · 2023: $256 · 2024: $554 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243 · Travel and Lodging: $167 · Education: $67.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.98 |
| Travel and Lodging | $167.20 |
| Education | $67.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $310.48 | 2022-2024 | Xospata, Vyloy |
| Pfizer INC. | $218.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $204.74 | 2019-2025 | |
| Beone Medicines USA, INC. | $201.75 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $150.68 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $143.30 | 2019-2025 | Lynparza |
| Amgen INC. | $128.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $121.74 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| E.R. Squibb & Sons, L.L.C. | $104.39 | 2019-2024 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $95.71 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $93.54 | 2019-2025 | |
| Abbvie INC. | $84.35 | 2019-2025 | Venclexta |
| Jazz Pharmaceuticals INC. | $75.84 | 2021-2025 | |
| Lilly USA, LLC | $68.15 | 2019-2025 | Verzenio |
| Seagen INC. | $53.17 | 2021-2023 | Padcev |
Show all 43 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Strother listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.